Ferring Reports Positive Data on Microbiota Treatment for C. Difficile Infection

Ferring Pharmaceuticals posted positive data on an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment.

In a presentation at the American College of Gastroenterology’s annual scientific meeting in Charlotte, N.C., Oct. 21-Oct. 26, the company released the results of several studies including one that analyzed the effect of the drug candidate RBX2660 on health-related quality of life.

The analyses showed greater improvements in health-related quality of life for patients treated with RBX2660 compared to placebo.

RBX2660 was developed by Ferring subsidiary Rebiotix. It was recommended by the FDA’s Vaccines and Related Biological Products Advisory Committee in September for recurrent C. difficile infections but has yet to gain FDA’s approval.

The agency has already granted RBX2660 Orphan Drug and Breakthrough Therapy designations.